EFFECTIVENESS OF SMS 201-995, A SYNTHETIC, LONG-ACTING SOMATOSTATIN ANALOGUE, IN TREATMENT OF QUININE-INDUCED HYPERINSULINAEMIA

R. E. PhillipsS. LooareesuwanS. R. BloomD. A. WarrellR. C. TurnerD. QuantrillA. R. MooreMahidol UniversityJohn Radcliffe HospitalHammersmith Hospital2018-02-272018-02-271986-03-29The Lancet. Vol.327, No.8483 (1986), 713-716014067362-s2.0-0022593162https://repository.li.mahidol.ac.th/handle/20.500.14594/9809SMS 201-995, a new long-acting, synthetic somatostatin analogue, dose 50 μg/h, given as a continuous intravenous infusion, completely abolished quinine-induced insulin release in 9 healthy Thai volunteers. Hyperinsulinaemia, which caused sustained hypoglycaemia in a 32-year-old post-partum Thai patient who was receiving intravenous quinine for falciparum malaria, was suppressed within 30 min of starting SMS 201-995, and the patient became fully conscious. This octapeptide antagonises the stimulatory effect of quinine on the pancreatic beta cell and is a specific therapy for life-threatening hyperinsulinaemic hypoglycaemia complicating falciparum malaria. © 1986.Mahidol UniversityMedicineEFFECTIVENESS OF SMS 201-995, A SYNTHETIC, LONG-ACTING SOMATOSTATIN ANALOGUE, IN TREATMENT OF QUININE-INDUCED HYPERINSULINAEMIAArticleSCOPUS10.1016/S0140-6736(86)91103-7